CDKN1A and acute myeloid leukemia: Ranganathan et al. (Ranganathan et al., 2015) also found that sequential treatment of AML cells with decitabine followed by XPO1 inhibitors can upregulate the expression of CDKN1A and FOXO3A, enhance anti-leukemia activity, and significantly extend the survival of AML mice compared to monotherapy with selinexor.